| | Webinar: Digitize Remote Site Monitoring with Box Tuesday, October 13 | 2pm ET / 11am PT Fierce Pharma is teaming up with Box to discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing. Accelerate R&D processes across the value chain, maintain GxP compliance and reduce your overall IT footprint. Save Your Spot! |
Amid White House feud, FDA raises vaccine rules that would nix a pre-election COVID shot BioNTech, Pfizer start rolling EMA approval filing for COVID-19 vaccine 5 ways medical practices can restore patient visit volumes amid a pandemic: report Pfizer-BioNTech, Regeneron sued for patent infringement with COVID-19 products How industry groups say Medicare payment rule proposals will hurt practices already besieged by COVID-19 After ERT hit by ransomware attack, the trial company kicks out old chief amid delayed COVID-19 work Oxford Biomedica earns U.K. nod for 4th manufacturing suite to boost COVID-19 production Novo Nordisk debuts animated Rybelsus ad after COVID-19 nixed film shoot Biopharma roundup: FDA posts vaccine rules despite White House feud; Saliva tests take off in the US: report Healthcare roundup: HCSC to offer $240M in premium relief to fully insured customers Walden Biosciences launches with $51M and a 2-pronged approach to 'completely transform' kidney disease Featured Story | By Eric Sagonowsky A weeks-long feud between the White House and FDA over COVID-19 vaccine guidelines took another turn Tuesday as the agency released vaccine recommendations despite efforts by the White House to keep them under wraps. The FDA advises two months of monitoring after patients' final doses, which could thwart President Donald Trump's desire for a shot before the election. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor BioNTech and Pfizer have started a rolling submission of their COVID-19 vaccine BNT162b2 to the European Medicines Agency (EMA). The news comes days after EMA named AstraZeneca's AZD1222 as the first COVID-19 vaccine to start the rolling review process. read more By Tina Reed In a report out this week, MGMA released key best practices for practices to follow to help restore patient volumes and stabilize financial footing based on 2019 data from more than 1,500 organizations. read more By Angus Liu As Regeneron grabs the limelight for treating President Donald Trump with its experimental COVID-19 antibody cocktail, the company now finds itself alongside vaccine developers Pfizer and BioNTech on the defensive in a lawsuit that claims their coronavirus products infringe upon a patent by Allele Biotech. read more By Heather Landi Proposed policy changes for Medicare payments for 2021 could hurt physician practices already experiencing severe reductions in revenue during the COVID-19 pandemic, according to several industry groups. read more By Ben Adams Clinical trial health tech firm eResearchTechnology is getting a new CEO in the same week a report by The New York Times said its work on COVID-19 treatments was delayed due to a cyberattack. read more By Kyle Blankenship Among the contract manufacturers enjoined in the race for a COVID-19 vaccine, U.K.-based Oxford Biomedica has forged a close relationship with AstraZeneca given its choice location. Now, the company is one step closer to running at full speed with the U.K.'s nod for a new production suite. read more By Sharon Klahr Coey Novo Nordisk’s first DTC ad for Rybelsus shows an animated world that looks a lot better than the real one currently does. But the sunny cartoon world wasn't Novo's original plan. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner The FDA is working to prevent interference in its vaccine reviews, Commissioner Hahn said. The agency on Tuesday released tougher guidelines for vaccine authorization. Saliva testing is gaining traction in the U.S. China is angling for WHO to review its vaccines. And eResearchTechnology switched CEOs after a ransomware attack stalled COVID trials. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Amy Sokolow In the U.S., about 37 million people live with kidney disease, which is more than 1 in 7 American adults. But Blaine McKee, the CEO of the newly unveiled Cambridge, MA, startup Walden Biosciences, hopes to change that. read more |
